Published Date : Jan 25, 2016
ALBANY, New York, January 25, 2016- MarketResearchReports.biz announces the addition of a recent report, titled ‘PharmaPoint: Peripheral Artery Disease - Global Drug Forecast And Market Analysis To 2024’, to its online repository. As per the report, the global peripheral artery disease market stood at US$543.4 mn in 2014, including both generic and branded drugs. The market is expected to reach US$816.3 mn by 2024, progressing at a 4.15% CAGR during the period from 2014 to 2024.
Peripheral artery disease (PAD), also known as peripheral vascular disease (PVD), results in the narrowing of arteries other than the ones that supply blood to the brain or the heart. PAD most commonly affects the legs and pain in the legs is the primary symptom. However, skin ulcers, poor nail growth, cold skin, and bluish skin are some of the other symptoms of peripheral artery disease. Cigarette smoking, diabetes, high blood cholesterol, and high blood pressure are some of the risk factors associated with PAD. Peripheral artery disease can be treated with angiography. The increasing occurrence of peripheral artery diseases across the globe is predicted to propel the global peripheral artery disease market during the period between 2014 and 2024.
The arrival of novel antithrombotic agents including Xarelto and Brilinta and the rising occurrence of PAD across all regional segments are two of the major factors expected to drive the global peripheral artery disease market in the years to come. However, factors such as market exclusivity of key pipeline drugs and marketed drugs and losses of patent protection are predicted to restrict the growth of the global peripheral artery disease market in the next few years. Market exclusivity on key pipeline drugs and marketed drugs such as Sanofis Plavix, Brilinta, Xarelto, and AstraZenecas will have an impact on the growth of the global peripheral artery disease market.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/511689
At present, the level of unmet demand in the global peripheral artery disease market is high. This is expected to generate growth opportunities for the global peripheral artery disease market in the next five years. There is a growing demand for therapies that target the symptoms of peripheral artery disease in CLI and IC patients. The demand for second-generation therapies and drug treatments that offer favorable safety profiles and superior efficacy is expected to increase in the coming years as well. Factors such as the requirement for physician education, greater screening, patient awareness, and improved guidelines for medical therapies are further expected to hamper the growth of the global peripheral artery disease market in the near future.
The increasing occurrence of PAD is expected to increase the frequency of the launch of various PAD drugs and treatment options across the globe. The new antithrombotic pharmacological agents such as Merck & Co.’s Zonitivity and AstraZeneca’s Brilinta are expected to have the capability to reform the anticoagulatory and antiplatelet PAD treatment landscape.
Some of the leading companies in the global peripheral artery disease market are Bayer, Janssen (Johnson & Johnson), AstraZeneca, Merck & Co., Sanofi, Pfizer, Bristol-Myers Squibb, Otsuka Holdings. The global peripheral artery disease market is predicted to be highly competitive with the entry of new companies.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org